An official website of the United States government

Publication Information

PubMed ID
Public Release Type
Journal
Publication Year
2022
Affiliation
Division of Cardiology, b Division of Nephrology, c Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Verona, Verona and d DepartDepartment of Pharmaceutical Sciences, School of Specialization in Hospital Pharmacy, University of Milan, Milan, Italy
Authors
Bignaminid AA, Gambaroa A, Gambaro G, Lombardib G, Mantovanic A, Ribichinia FL
Studies

Abstract

Blood pressure control, which can induce a slight decrease in the glomerular filtration rate (GFR), plays a nephron- and cardioprotective role. However, the more important early decline in GFR associated with antihypertensive therapy and strict blood pressure targets is still of concern. Since few data are available from trials and observational studies, and the phenomenon is relatively rare, we performed a metaanalysis of available studies. We conclude that major reductions in the glomerular filtration rate occurring soon after starting angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and/or under intensive blood pressure control predict end-stage kidney disease